Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
ADXN Stock Chart & Stats
$8.23
$0.23(2.80%)
At close: 4:00 PM EST
$8.23
$0.23(2.80%)
Day’s Range― - ―
52-Week Range$6.51 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)16.10K
Market Cap
$9.16M
Enterprise Value$5.18M
Total Cash (Recent Filing)$2.19M
Total Debt (Recent Filing)$36.55K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Mar 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,822,121
10 Day Avg. Volume4,441
30 Day Avg. Volume16,099
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.54
Price to Sales (P/S)12.86
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue76.64
Enterprise Value/Gross Profit-31.06
Enterprise Value/Ebitda-0.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetA very low-debt capital structure materially reduces refinancing and interest-rate risk for a cash-burning clinical-stage biotech. This gives management flexibility to prioritize R&D, pursue partnerships or outlicense assets, and buy time for milestone-driven financing without immediate solvency pressure.
Material Partnership Milestone UpsideA partnership with milestone payments up to $330M provides a durable, non-dilutive funding pathway if development succeeds. Structurally, milestone-linked receipts can fund further development, validate programs via partner investment, and materially derisk capital demands compared with sole reliance on equity financing.
Peer-reviewed Pipeline ValidationA peer-reviewed publication demonstrating mechanistic and human tissue support strengthens scientific validation of a program. Durable impacts include improved partner/partnering-agency confidence, stronger IP/clinical rationale, and a higher probability that preclinical findings will attract collaborations or licensing over the coming months.
Bears Say
Shrinking Revenue And Weak MarginsPersistent revenue decline and deeply negative operating/net margins show core operations do not cover costs. Over 2-6 months this limits reinvestment in R&D, heightens dependency on external funding or partner milestones, and weakens the company's ability to absorb trial setbacks without significant financing or asset sales.
Negative Cash Flow And Limited RunwayNegative operating and free cash flow indicate continued cash burn; management reported CHF 2.2M at Q3 2025 and runway to mid-2026. This creates near-term financing pressure: unpartnered programs cannot progress without new capital, increasing dilution or deal risk and constraining strategic optionality.
Revenue Dependent On Partner MilestonesA business model reliant on upfronts, milestones and royalties yields lumpy, binary cash flows tied to partner decisions and clinical success. This structural dependence elevates timing risk and makes revenue streams contingent on external development and commercialization choices beyond the firm's direct control.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $6.51 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $9.16M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 14 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Dec 04, 2025. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.785%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
ADXN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---